Ethyl eicosapentaenoic acid: Difference between revisions

Line 111:

The most common side effects are musculoskeletal pain, peripheral edema (swelling of legs and hands), atrial fibrillation, and arthralgia (joint pain). Other common side effects include bleeding, constipation, gout, and rash.

It is made from the [[omega-3 fatty acid]] [[eicosapentaenoic acid]] (EPA). The US [[Food and Drug Administration]] (FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second [[fish oil]]-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels".~~<ref name="FDA PR"/>~~ It is available as a [[generic medication]]. In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.

It is made from the [[omega-3 fatty acid]] [[eicosapentaenoic acid]] (EPA). The US [[Food and Drug Administration]] (FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second [[fish oil]]-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels". It is available as a [[generic medication]]. In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.

==Medical uses==

Line 158:

== Society and culture ==

=== Legal status ===

On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the [[European Medicines Agency]] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vazkepa, intended to reduce the risk of cardiovascular events in people at high cardiovascular risk.~~<ref name="Vazkepa: Pending EC decision" />~~ The applicant for this medicinal product is [[Amarin Pharmaceuticals]] Ireland Limited. It was approved for medical use in the European Union in March 2021.

On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the [[European Medicines Agency]] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vazkepa, intended to reduce the risk of cardiovascular events in people at high cardiovascular risk. The applicant for this medicinal product is [[Amarin Pharmaceuticals]] Ireland Limited. It was approved for medical use in the European Union in March 2021.

@@ Line 111: / Line 111: @@
 The most common side effects are musculoskeletal pain, peripheral edema (swelling of legs and hands), atrial fibrillation, and arthralgia (joint pain). Other common side effects include bleeding, constipation, gout, and rash.
-It is made from the [[omega-3 fatty acid]] [[eicosapentaenoic acid]] (EPA). The US [[Food and Drug Administration]] (FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second [[fish oil]]-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels".<ref name="FDA PR"/> It is available as a [[generic medication]]. In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.
+It is made from the [[omega-3 fatty acid]] [[eicosapentaenoic acid]] (EPA). The US [[Food and Drug Administration]] (FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second [[fish oil]]-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels". It is available as a [[generic medication]]. In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.
 ==Medical uses==
@@ Line 158: / Line 158: @@
 == Society and culture ==
 === Legal status ===
-On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the [[European Medicines Agency]] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vazkepa, intended to reduce the risk of cardiovascular events in people at high cardiovascular risk.<ref name="Vazkepa: Pending EC decision" /> The applicant for this medicinal product is [[Amarin Pharmaceuticals]] Ireland Limited. It was approved for medical use in the European Union in March 2021.
+On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the [[European Medicines Agency]] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vazkepa, intended to reduce the risk of cardiovascular events in people at high cardiovascular risk. The applicant for this medicinal product is [[Amarin Pharmaceuticals]] Ireland Limited. It was approved for medical use in the European Union in March 2021.
 {{Lipid modifying agents}}